ASCO 2011

TickerPriceDrugIndicationStageAbstract LINKSession TypeDate/Time
AGEN6.31HSPPC-96Cancer - recurrent gliomaPhase 2#2565General Poster Session Mon, Jun 6 8:00 AM - 12:00 PM
ALTH1.82PralatrexateCancer - NSCLCPhase 2b#7554General Poster Session Sat, Jun 4 2:00 PM - 6:00 PM
ALNY11.19ALN-VSP02Cancer - solid tumors with liver involvementPhase 1#3025Poster Discussion SessionSat, Jun 4 2:00 PM - 6:00 PM
ARIA15.28RidaforolimusCancer - BreastPhase 2#TPS110Trials in Progress Poster Session Mon, Jun 6 8:00 AM - 12:00 PM
ARIA15.28Oral ponatinibCancer - chronic myeloid leukemia, acute lymphoblastic leukemiaPhase 1#6518Poster Discussion Session Fri, Jun 3 2:00 PM - 6:00 PM
ARIA15.28RidaforolimusCancer - Endometrial Phase 2#5009Oral Abstract Session 5:00 PM - 5:15 PM
ARIA15.28RidaforolimusCancer - EndometrialPhase 2#5013Poster Discussion Session Fri, Jun 3 2:00 PM - 6:00 PM
ARIA15.28RidaforolimusCancer - SarcomaPhase 3#10005Oral Abstract Session Mon, Jun 6 4:30 PM - 4:45 PM
ARQL7.19ARQ 197Cancer - metastatic colorectalPhase 1#3582General Poster Session Sat, Jun 4 8:00 AM - 12:00 PM
ARQL7.19ARQ 197Cancer - relapsed or refractory germ cell tumors (GCTs).Phase 2#4638General Poster Session Sun, Jun 5 8:00 AM - 12:00 PM
ARQL7.19ARQ 197Cancer - advanced breast, ovarian, and uterine tumorsPhase 1b#3077General Poster SessionMon, Jun 6 8:00 AM - 12:00 PM
ARQL7.19ARQ 621Cancer - solid tumorsFirst-in-human study#3076General Poster SessionMon, Jun 6 8:00 AM - 12:00 PM
ARQL7.19ARQ 197Cancer - variousPhase 1#3034General Poster Session Mon, Jun 6 8:00 AM - 12:00 PM
ARQL7.19ARQ 197Cancer - NSCLCPhase 3#TPS217Trials in Progress PosterMon, Jun 6 8:00 AM - 12:00 PM
ARRY3.59AZD6244Cancer - advanced solid malignanciesPhase 1#TPS156Trials in Progress Poster Mon, Jun 6 8:00 AM - 12:00 PM
ARRY3.59AZD6244 Cancer - advanced solid tumoursPhase 1#3004Oral Abstract Session Sun Jun 5, 10:00 AM - 10:15 AM
ARRY3.59Oral selumetinibCancer - metastatic solid tumorsPhase 1#3004Oral Abstract Session Sun, Jun 5 9:30 AM - 12:30 PM
BPAX0.54GM-CSF vaccineCancer - HER2+ metastatic breastFeasibility study#2535Poster Discussion Session Sat Jun 4, 2011
CRIS4.77GDC-0449Cancer - GastricPhase 2TPS173Trials in Progress PosterMon Jun 6, 2011, 8:00 AM - 12:00 PM
CRIS4.77GDC-0449Cancer - solid tumorsPhase 13092General Poster Session Mon Jun 6, 2011, 8:00 AM - 12:00 PM
CRIS4.77GDC-0449Cancer - non-small cell lung cancer (NSCLC)10537General Poster SessionMon Jun 6, 2011, 8:00 AM - 12:00 PM
CTIC1.17PaclitaxelCancer - GliomaPhase 2#2036Poster Discussion SessionFri, Jun 3 2:00 PM - 6:00 PM
CTIC1.17OPAL - TosedostatCancer - relapsed or refractory acute myeloid leukemia (AML)Phase 1/2#6517Poster Discussion SessionFri, Jun 3 2:00 PM - 6:00 PM
CYCC0.58SapacitabineCancer - Myelodysplastic syndromesPhase 2#6587General Poster Session Mon Jun 6, 2011, 1:00 PM - 5:00 PM
ENMD2.07ENMD-2076Cancer - OvarianPhase 2#5021Poster Discussion Session Fri Jun 3, 2:00 PM - 6:00 PM
EXEL4.78XL184Cancer - metastatic castration-resistant prostatePhase 2#4516Oral Abstract Session Mon Jun 6 1:15 PM - 1:30 PM
EXEL4.78XL184 Cancer - advanced solid tumors.Phase 2#CRA3010Oral Abstract Session Sun Jun 5, 12:00 PM - 12:15 PM
EXEL4.78XL184Cancer - advanced ovarian cancerPhase 2#5008Oral Abstract SessionSaturday June 4, 3:00 PM to 6:00 PM
GTXI3.31GTx-024Cancer - non-small cell lung cancer (NSCLC)Phase 2b#9022Poster Discussion SessionSunday June 5, 8:00 AM to 12:00 PM
GTXI3.31GTx-0,024Cancer - non-small cell lung cancer (NSCLC)Phase 2b#9117Poster Discussion SessionSaturday June 4, 2:00 PM to 6:00 PM
IMGN12.46T-DM1 Plus capecitabine cf pertuzumabCancer - 2nd-line HER2+ Metastatic Breast CancerPhase 2#TPS118Trials in Progress Poster Session Mon, Jun 6 8:00 AM - 12:00 PM
IMGN12.46Trastuzumab-DM1 cf pertuzumabCancer - 1st-line HER2+ Metastatic Breast Cancer Phase 3#TPS102Trials in Progress Poster Session Mon, Jun 6 8:00 AM - 12:00 PM
IMGN12.46Trastuzumab-DM1 cf lapatinibCancer - 1st-line HER2/neu-positive metastatic breast cancerPhase 3#TPS108Trials in Progress Poster SessionMon, Jun 6 8:00 AM - 12:00 PM
IMGN12.46Trastuzumab-DM1Cancer - 2nd-line HER2+ MBCPhase 3#TPS116Trials in Progress Poster SessionMon, Jun 6 8:00 AM - 12:00 PM
IMGN12.46IMGN901 (lorvotuzumab mertansine)Cancer - Merkel cell carcinomaPhase 1#8013Oral Abstract Session Sun Jun 5, 11:30 AM - 11:45 AM
INCY18.77INCB18424Cancer- myelofibrosisPhase 3#6500Oral Abstract Session Mon, Jun 6 9:30 AM - 12:30 PM
INCY18.77JAK inhibitor ruxolitinib (INC424)Cancer- myelofibrosisPhase 3#6501Oral Abstract Session Monday June 6, 9:30 AM to 12:30 PM
INFI12.53Retaspimycin HydrochlorideCancer - Breast Phase 2#590General Poster Session Mon, Jun 6 1:00 PM - 5:00 PM
INFI12.53IPI-926Cancer - advanced or metastatic solid tumorsPhase 1#3014Poster Discussion Session Sat Jun 4 2:00 PM - 6:00 PM
INFI12.53Retaspimycin HydrochlorideCancer - NSCLCPhase 2??#7516Poster Discussion Session Mon, Jun 6 2:00 PM - 6:00 PM
INFI12.53IPI-926Cancer - PancreaticPhase 1b/2#4114General Poster SessionSat Jun 4 8:00 AM - 12:00 PM
ISIS7.59LY2181308Cancer - first-line treatment of castrate-resistant prostate cancer (CRPC).Phase 2#4592General Poster SessionSun, Jun 5 8:00 AM - 12:00 PM
ISIS7.59OGX-011 Cancer - prostatePhase 3#4502Clinical Science Symposium Sat, Jun 4 1:15 PM - 2:45 PM
ISIS7.59OGX-011Cancer - prostate#4573General Poster Session Sun, Jun 5 8:00 AM - 12:00 PM
LGND13.95DinaciclibCancer - relapsed/refractory CLLPhase 2#6623General Poster SessionMon, Jun 6 1:00 PM - 5:00 PM
LGND13.95CarfilzomibCancer - multiple myelomaPhase 3#TPS225Trials in Progress Poster Session Mon, Jun 6 8:00 AM - 12:00 PM
LGND13.95Eltrombopaghuman cord blood hematopoietic stem cell/primitive progenitor cell expansion.#6632General Poster Session Mon, Jun 6 1:00 PM - 5:00 PM
LGND13.95Melphalan HClCancer - multiple myelomaPhase 2a#6571General Poster SessionMon, Jun 6 1:00 PM - 5:00 PM
LGND13.95SCH 727965Cancer - variousPhase 1#3080General Poster SessionMon, Jun 6 8:00 AM - 12:00 PM
MDVN74.82MDV3100Cancer - prostate#4502Clinical Science Symposium Sat Jun 4 2011, 2:30 PM - 2:45 PM
MYRX3.01Azixa - Verubulin (MPC-6827)Cancer - recurrent glioblastomaPhase 2#2088General Poster Session Sat, Jun 4 8:00 AM - 12:00 PM
NEOP#N/ALymphoseek/ tilmanoceptLymphatic-tissue tracing agentPhase 3Clinical Problems in Oncology Session Sat, Jun 4 5:05 PM - 5:25 PM
NEOP#N/ALymphoseek/ tilmanoceptLymphatic-tissue tracing agentPhase 3#LBA8526Poster Discussion Session Mon, Jun 6 8:00 AM - 12:00 PM
NKTR7.49NKTR-102Cancer - breastPhase 21034Poster Discussion Session Jun 4, 2-6pm and 5-6pm
NKTR7.49NKTR-102Cancer - solid tumours2598General Poster Session Jun 6, 8am - 12noon
NKTR7.49NKTR-102Cancer - ovarian#5047General Poster Session Jun 5 8am-12noon
ONTY4.01L-BLP25Cancer - Gastrointestinal (Colorectal) CancerPhase 2#TPS166Trials in Progress Poster SessionMonday June 6, 8:00 AM to 12:00 PM
OGXI12.35OGX-011 Cancer - prostatePhase 3#4502Clinical Science Symposium Sat, Jun 4 1:15 PM - 2:45 PM
OGXI12.35OGX-011Cancer - prostate#4573General Poster Session Sun, Jun 5 8:00 AM - 12:00 PM
OXGN0.95ZYBRESTATCancer - ATC Phase 2/3#5502Oral Abstract Session Mon, Jun 6 3:45 PM - 4:00 PM
OXGN0.95ZYBRESTATCancer - NSCLCPhase 2#7559General Poster Session Sat, Jun 4 2:00 PM - 6:00 PM
PCYC26.29PCI-32765Cancer - CLL/small lymphocytic lymphomaPhase 1b/2#6508Oral Abstract Session Mon, Jun 6 12:00 PM - 12:15 PM
PPHM0.41CotaraCancer - glioblastoma multiforme (GBM)Phase 2#2035Poster Discussion SessionFriday June 3, 2:00 PM to 6:00 PM
RXII#N/ATrastuzumab + CD8 T-cell-eliciting HER2/neu peptide vaccineCancer - breastPhase 2#564Poster Discussion SessionMonday June 6, 1:00 PM to 5:00 PM
SGEN19.3LintuzumabCancer - Acute myeloid leukemia AMLPhase 1#6516Poster Discussion Session Fri Jun 3, 2:00 PM - 6:00 PM
SGEN19.3Brentuximab VedotinCancer - Anaplastic large cell lymphomaBLA#8032General Poster SessionMon Jun 6, 1:00 PM - 5:00 PM
SGEN19.3Brentuximab Vedotin Cancer - Relapsed & Refractory Hodgkin lymphomaBLA#8031General Poster SessionMon Jun 6, 1:00 PM - 5:00 PM
SNSS2.85VosaroxinCancer - Acute myeloid leukemia AMLPhase 3#TPS201Trials in Progress Poster SessionMon Jun 6, 8:00 AM - 12:00 PM
SNTA4.27GanetespibCancer - solid tumoursPhase 1#3051General Poster Session Mon Jun 6, 8:00 AM - 12:00 PM
SNTA4.27GanetespibCancer - NSCLCPhase 2#7500Clinical Science SymposiumSat Jun 4, 8:00 AM - 8:15 AM
SNTA4.27GanetespibCancer - metastatic and/or unresectable GIST.Phase 2#10011Poster Discussion Session Sat Jun 4, 8:00 AM - 12:00 PM
SPPI10.36BelinostatCancer - Carcinoma of Unknown Primary (CUP)Phase 1#6521Poster Discussion Session Fri Jun 3, 2:00 PM - 6:00 PM
SUPG0Dacogen (decitabine)Acute myeloid leukemia (AML). Phase 3#6504Oral Abstract Session Mon, Jun 6, 10:45 AM - 11:00 AM
SUPG0Dacogen (decitabine)Acute myeloid leukemia (AML).Phase 2#6537General Poster Session Mon, Jun 6 1:00 PM - 5:00 PM
SUPG0Dacogen (decitabine)Recurrent platinum (Pt)-resistant ovarian cancerPhase 2#5011Oral Abstract Session Sat Jun 4, 5:30 PM - 5:45 PM
SUPG0Dacogen (decitabine)Cancer - melanomaPhase 1/2#8530Poster Discussion Session Mon, Jun 6 8:00 AM - 12:00 PM
SUPG0Amuvatinib (MP-470)Cancer - disrupts various cancer cellsPhase 1b#3074General Poster Session Mon, Jun 6 8:00 AM - 12:00 PM
THLD6.75TH-302Cancer - PancreaticPhase 2#TPS176Trials in Progress Poster SessionMon Jun 6 8:00 AM - 12:00 PM
THLD6.75TH-302Cancer - soft tissue sarcomaPhase 3#10024Poster Discussion Session Sat Jun 4, 8:00 AM - 12:00 PM
VICL2.92Allovectin-7Cancer - melanomaPhase 2#8572General Poster Session Sun Jun 5, 8:00 AM - 12:00 PM
YMI1.69CYT387Cancer - myelofibrosisPhase 1/2#6514Poster Discussion SessionFri Jun 3, 2:00 PM - 6:00 PM
YMI1.69NimotuzumabCancer - glioblastomaPhase 3#2059General Poster Session Sat, Jun 4 8:00 AM - 12:00 PM
YMI1.69NimotuzumabCancer - Child gliomaPhase 1?#9557General Poster SessionSun, Jun 5 8:00 AM - 12:00 PM
ZIOP4.92DC-RTS-IL-12Cancer - Anticancer ProteinPhase 1b#2540General Poster SessionMonday June 6, 8:00 AM to 12:00 PM

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “ASCO 2011”

Leave a Reply